Structural formula: Carmustine

GLIADEL 7.7 mg, implant 8 implants

Telegram WhatsApp

Link to share

Active ingredients: Carmustine

Commercialized according to BDPMDispensing in France: Prescription only, hospital use

Implant8 implantsintralésionnelle

No current ANSM shortage notice is included

Package details

Original BDPM fields are shown in French.

Official name: GLIADEL 7,7 mg, implant
Pharmaceutical form: implant
Route of administration: intralésionnelle
Presentation description: 8 sachet(s)-dose(s) aluminium de 1 implant(s)
Marketing authorisation holder: CLINIGEN HEALTHCARE (PAYS BAS)
Reimbursement according to BDPM: —
Approval for use in healthcare institutions: oui
Commercialization declaration date: 13 Sept 1999
Prescription and dispensing conditions: Prescription only, hospital use
List I: prescription-only medicine
Requires special monitoring during treatment
Prescribed by specialists only
Hospital use only
Original BDPM wording: liste I · médicament nécessitant une surveillance particulière pendant le traitement · prescription réservée aux médecins compétents en CANCEROLOGIE · prescription réservée aux spécialistes et services HEMATOLOGIE · prescription réservée aux spécialistes et services NEUROCHIRURGIE · prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE · réservé à l'usage HOSPITALIER
Enhanced ANSM monitoring: No

BDPM identifiers

CIS67758269CIP75619075CIP133400956190751

Composition in BDPM

Composition in BDPM
Component	Amount per unit	Source type
CARMUSTINEimplant	7,7 mg · un implant	SA

Information is based on BDPM data and is for reference only. Consult a doctor before use.

Similar medicines

Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.

The current BDPM data does not list similar medicines for this product.